HTG Molecular Diagnostics Total Liabilities

HTG Molecular Diagnostics (HTGM) currently reports a total liabilities of $10M as of March 2023. That compares with $17M in the prior-year period — down 39.6% year over year. Use the charts on this page to explore HTG Molecular Diagnostics's total liabilities history and peer comparisons.

HTG Molecular Diagnostics's total liabilities decreased from $17M to $10M — a 39.6% year-over-year decrease (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

HTG Molecular Diagnostics reported $10M in total liabilities as of March 2023. That compares with $17M in the prior-year period — down 39.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $10M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for HTG Molecular Diagnostics, and consider following HTGM for alerts when major investors trade the stock.

HTG Molecular Diagnostics is classified in the Healthcare sector. On total liabilities, it currently shows $10M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HTGM with unrelated industries.